Medline, Inc. Class A (MDLN) Gets a Buy from RBC Capital

RBC Capital analyst Ryan Halsted maintained a Buy rating on Medline, Inc. Class A yesterday and set a price target of $47.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Halsted covers the Healthcare sector, focusing on stocks such as Sotera Health, Privia Health Group, and Doximity. According to TipRanks, Halsted has an average return of 3.8% and a 57.14% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Medline, Inc. Class A with a $47.24 average price target.

Based on Medline, Inc. Class A’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $7.12 billion and a net profit of $322 million.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDLN in relation to earlier this year. Most recently, in December 2025, Carlyle Group L.P., a Major Shareholder at MDLN sold 19,136,333.00 shares for a total of $554,953,657.00.